Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas

• Verfasst von: Knecht, Susanne [VerfasserIn]
• Verfasst von: Heß, Jochen [VerfasserIn]
• Titel: Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas
• Verf.angabe: Susanne R. Tepper, Zhixiang Zuo, Arun Khattri, Jochen Heß, Tanguy Y. Seiwert
• E-Jahr: 2016
• Jahr: 26 March 2016
• Umfang: 9 S.
• Fussnoten: Gesehen am 28.10.2019
• Titel Quelle: Enthalten in: Oral oncology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1997
• Jahr Quelle: 2016
• Band/Heft Quelle: 56(2016), Seite 62-70
• ISSN Quelle: 1879-0593
• DOI: doi:10.1016/j.oraloncology.2016.03.008
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Drug resistance
• Sach-SW: Epidermal growth factor receptor
• Sach-SW: Gefitinib
• Sach-SW: Head and neck cancer
• Sach-SW: Squamous cell carcinoma
• Sach-SW: Tumor microenvironment
• K10plus-PPN: 1680539574

Abstract

Objectives - Epidermal growth factor receptor (EGFR)-targeted therapy is frequently used in the treatment of advanced head and neck squamous cell carcinoma (HNSCC). However, constitutive or acquired resistance is common and underlying resistance mechanisms remain poorly understood. We investigated the expression levels of growth factors (GF) in tumor-associated stroma and tumor from HNSCC patients and determined the influence of GFs on EGFR inhibitor efficacy in vitro. - Materials and methods - The Chicago HNC Genomic Cohort (CHGC) was queried for GF and receptor tyrosine kinase (RTK) expression. Viability assays were used to evaluate the effect of EGFR inhibition (gefitinib), GF treatment, or both in HNSCC cell lines. Caspase-based assays were used to measure apoptotic activity. Expression of RTKs was determined and correlated with GF treatment effects. - Results - Amphiregulin (AREG), transforming growth factor (TGFβ1), insulin like growth factor (IGF1), fibroblast growth factors (FGF1/FGF2) and the corresponding RTKs were highly expressed in 30-50% of HNSCC, and expression was usually concurrent. While EGFR inhibition was markedly efficacious in HNC cell lines (HN5/HN13/H400/SCC61), co-treatment with most GFs increased viability up to 100%. Only TGFβ1 treatment was additive to EGFR inhibition. GFs also reduced apoptotic effects of EGFR inhibition. RTK expression showed strong positive correlation with respective GF treatment effect for IGF1-IGF1R, less strong for HGF-MET/AREG-EGFR and a moderate negative correlation for TGFβ1-TGFBR1/2. - Conclusion - High expression of GFs/RTKs occurs in HNSCC. Co-expression is common. GF expression contributes to EGFR inhibition resistance in our model system, and may be a common mechanism of constitutive or acquired resistance to EGFR inhibition in HNSCC.